Showing 41,721 - 41,740 results of 42,037 for search 'Aleut~', query time: 2.05s Refine Results
  1. 41721
  2. 41722

    Problems and possibilities of studying malting quality in barley using molecular genetic approaches by N. V. Trubacheeva, L. A. Pershina

    Published 2021-04-01
    “…About one-third of the world’s barley crop is used for malt production to meet the needs of the brewing industry. …”
    Get full text
    Article
  3. 41723

    Metabolomic approach to search for fungal resistant forms of <i>Aegilops tauschii</i> Coss. from the VIR collection by T. V. Shelenga, L. L. Malyshev, Yu. A. Kerv, T. V. Diubenko, A. V. Konarev, V. I. Horeva, M. K. Belousova, M. A. Kolesova, N. N. Chikida

    Published 2020-05-01
    “…For instance, genes that determine resistance to rust agents in common wheat were successfully introgressed from Ae. tauschii into the genome of T. aestivum L. …”
    Get full text
    Article
  4. 41724

    Advances in Cell and Immune Therapies for Melanoma by Tanase Timis, Sanda Buruiana, Delia Dima, Madalina Nistor, Ximena Maria Muresan, Diana Cenariu, Adrian-Bogdan Tigu, Ciprian Tomuleasa

    Published 2025-01-01
    “…The incidence rate of cutaneous melanoma is on the rise worldwide, due to increased exposure to UV radiation, aging populations, and exposure to teratogen agents. However, diagnosis is more precise, and the increased number of new cases is related to the improved diagnosis tools. …”
    Get full text
    Article
  5. 41725

    NIR-triggered programmable nanomotor with H2S and NO generation for cascading oncotherapy by three-pronged reinforcing ICD by Jinlong Zhang, Quan Jing, Longlong Yuan, Xianhui Zhou, Duolong Di, Jinyao Li, Dong Pei, Zhongxiong Fan, Jun Hai

    Published 2025-04-01
    “…Gas therapy (GT) and/or phototherapy have been recently employed as immunogenic cell death (ICD) agents for activating immunotherapy, whereas the effective activation of sufficient immune responses remains an enormous challenge in such single therapeutic modality. …”
    Get full text
    Article
  6. 41726
  7. 41727

    Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis by Shunlian Fu, Pingjin Zou, Zengyi Fang, Xinxiang Zhou, Junyang Chen, Cuicui Gong, Li Quan, Bing Lin, Qiu Chen, Jinyi Lang, Meihua Chen

    Published 2025-01-01
    “…Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPi) serve as crucial therapeutic agents in solid tumor treatment. Preclinical investigations suggest a potential protective function of PARPi against endocrine and metabolic impairments. …”
    Get full text
    Article
  8. 41728

    Nina Façon şi tentaţia omului activ by Ana Bazac

    Published 2009-12-01
    “…Dopo un’introduzione sull’importanza della filosofia nell’opera di Nina Façon, in seguito a una breve analisi del concetto di attività – con insistenza sui suoi legami con la nozione di soggetto e con il motivo di Prometeo come modello culturale – la relazione ricorda alcune caratteristiche dell’uomo attivo, così come ritrovate negli studi di Nina Façon. …”
    Get full text
    Article
  9. 41729

    Cortina d’Ampezzo 1956 tra organizzazione sportiva e relazioni internazionali by Gherardo Bonini, Franco Cervellati, Marcello Marchioni

    Published 2025-01-01
    “…Oltre alla possibile problematicità legata al funzionamento degli impianti e alla gestione dei Giochi, il Comitato organizzatore si confrontò con alcune controversie sul piano delle relazioni internazionali. …”
    Get full text
    Article
  10. 41730

    Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies by Yizhou Zhang, Ruicheng Wei, Ge Song, Xinyi Yang, Mengli Zhang, Wei Liu, Aiying Xiong, Xuehan Zhang, Qianhao Li, Wan-Jen Yang, Chencheng Han, Rui Liu, Chen Hu, Qingyu Wang, Jun Zhu, Yongqiang Shan

    Published 2024-12-01
    “…With more than 20 anti-PD-1/PD-L1 antibodies currently marketed, anti-PD-1 therapy has become a cornerstone of tumor immunotherapy. These agents, however, exhibit notable disparities in their characteristics and clinical performance. …”
    Get full text
    Article
  11. 41731

    The Influence of Ficus deltoidea in Preserving Alveolar Bone in Ovariectomized Rats by N. I. Omar, B. Baharin, S. F. Lau, N. Ibrahim, N. Mohd, A. Ahmad Fauzi, N. Muhammad, N. M. Fernandez

    Published 2020-01-01
    “…Treatment of the rats commenced two weeks after ovariectomy—the OVXP rats that served as positive control received Premarin® (64.5 μg/kg body weight), while OVXF rats were given F. deltoidea (800 mg/kg body weight); both agents were administered orally for two months. The negative control group of rats (OVXN) and the SO group received deionized water, also administered via oral gavage. …”
    Get full text
    Article
  12. 41732

    Rappresentazioni contemporanee per il progetto di paesaggio by Sara Colaceci

    Published 2024-12-01
    “… Questo saggio affronta le tematiche inerenti alla rappresentazione contemporanea per il progetto di paesaggio tramite alcune esperienze significative sviluppate dagli anni ’90 del XX secolo ad oggi, nati dalla collaborazione di architetti, di paesaggisti, di artisti tra i quali Yves Brunier, Enric Miralles, Inside Outside (studio fondato da Petra Blaisse), Mark Smout, Laura Allen, Teresa Moller Landscape Studio (studio fondato da Teresa Moller), Openfabric (studio fondato da Francesco Garofalo), 08014 arquitectura (studio fondato da Adrià Guardiet e Sandra Torres), Mir (studio fondato da Mats Andersen e Trond Greve Andersen). …”
    Get full text
    Article
  13. 41733

    Diagnostics and treatment of pancreatic exocrine insufficiency: clinical guidelines of the Russian gastroenterological association by V. T. Ivashkin, I. V. Mayev, A. V. Okhlobystin, S. A. Alekseyenko, Ye. V. Beloborodova, Yu. A. Kucheryavy, T. L. Lapina, A. S. Trukhmanov, I. B. Khlynov, M. V. Chikunova, A. A. Sheptulin, O. S. Shifrin

    Published 2018-08-01
    “…Digestive enzymes should be taken at the beginning of the meal, in the case of incomplete response it can be recommended to use antisecretory agents. Patient should be consulted by nutritionist, no significant limitation of fat intake is recommended. …”
    Get full text
    Article
  14. 41734
  15. 41735
  16. 41736

    Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML by Julia M. Unglaub, Richard F. Schlenk, Jan Moritz Middeke, Stefan W. Krause, Sabrina Kraus, Hermann Einsele, Michael Kramer, Sven Zukunft, Joseph Kauer, Simon Renders, Elena Katelari, Christoph Schliemann, Caroline Pabst, Thomas Luft, Peter Dreger, Christoph Röllig, Martin Bornhäuser, Carsten Müller-Tidow, Tim Sauer

    Published 2025-01-01
    “…Abstract: The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. …”
    Get full text
    Article
  17. 41737
  18. 41738
  19. 41739

    Exploring the role of ELOVLs family in lung adenocarcinoma based on bioinformatic analysis and experimental validation by Zihan Wang, Wenjing Cui, Long Liang, Jingge Qu, Yuqiang Pei, Danyang Li, Ying Luo, Yue Zhang, Yifan Qiu, Yongchang Sun

    Published 2025-01-01
    “…Meanwhile, patients with low-ELOVL6 expression were more sensitive to the 4 representative chemotherapeutic agents. In vitro, we revealed that interfering with ELOVL6 could influence the viability, proliferation, migration capacity and fatty acid metabolism of LUAD cells (A549 and H1299). …”
    Get full text
    Article
  20. 41740

    Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer by Satomi Watanabe, Kimio Yonesaka, Junko Tanizaki, Yoshikane Nonagase, Naoki Takegawa, Koji Haratani, Hisato Kawakami, Hidetoshi Hayashi, Masayuki Takeda, Junji Tsurutani, Kazuhiko Nakagawa

    Published 2019-03-01
    “…The effects of these agents were then evaluated in vivo using BT474‐HRG and an intrinsic heregulin‐expressing and HER2‐positive JIMT‐1 xenograft models. …”
    Get full text
    Article